In the ongoing clinical trials (Table 1), IL-1β inhibition is being assessed in BC, with special focus on analyzing immune biomarkers including TILs, TAMs, NK cells, IL-1β, and inflammasome components (see Section 3). The gene discussed is IL1B; the disease is breast cancer.